세계의 골수섬유증(MF) 시장 보고서(2025년)

Myelofibrosis (MF) is a rare bone marrow disorder marked by the excessive formation of scar tissue, which impairs the normal production of blood cells. This condition can cause anemia, an enlarged spleen, and symptoms such as fatigue, night sweats, and bone pain.

The primary drug types used for treating myelofibrosis include JAK inhibitors, immunomodulators, hydroxyurea, and other therapies. JAK inhibitors are medications that block Janus kinase enzymes, which are involved in signaling pathways responsible for inflammation, immune response, and cell growth. These inhibitors are commonly used to treat conditions such as rheumatoid arthritis and myelofibrosis. Treatment options for MF include chemotherapy, targeted therapy, and other types of treatment. The medications can be administered orally, parenterally, or through other routes. They are distributed via hospital pharmacies, online pharmacies, and retail pharmacies, with key end users including hospitals, home care settings, specialty clinics, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The myelofibrosis (MF) market research report is one of a series of new reports from The Business Research Company that provides myelofibrosis (MF) market statistics, including the myelofibrosis (MF) industry global market size, regional shares, competitors with the myelofibrosis (MF) market share, detailed myelofibrosis (MF) market segments, market trends, and opportunities, and any further data you may need to thrive in the myelofibrosis (MF) industry. This myelofibrosis (MF) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The myelofibrosis (mf) market size has grown steadily in recent years. It will grow from $1.5 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to the increasing prevalence of myeloproliferative neoplasms, rising awareness and early diagnosis, growing adoption of JAK inhibitors, expanding access to bone marrow transplants, and increasing regulatory approvals for new therapies.

The myelofibrosis (mf) market size is expected to see steady growth in the next few years. It will grow to $1.75 billion in 2029 at a compound annual growth rate (CAGR) of 3.1%. The growth in the forecast period can be attributed to rising demand for personalized treatment approaches, increasing clinical trials for gene and cell therapies, growing use of combination therapies, expanding healthcare coverage for rare diseases, and increasing investment in hematology care. Major trends in the forecast period include advancements in gene-editing technologies, innovation in fibrosis-targeting drugs, development of next-generation JAK inhibitors, growing interest in immunotherapy for myelofibrosis, and expanding use of artificial intelligence in drug discovery.

The forecast of 3.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of JAK2 inhibitors and bone marrow biopsy needles sourced from the UK and Belgium, exacerbating symptom management challenges and raising hematologic malignancy care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing demand for targeted therapies is expected to drive the growth of the myelofibrosis (MF) market. Targeted therapies are an approach that tailors treatments and healthcare decisions based on an individual's genetic, environmental, and lifestyle factors. The increasing demand for these therapies is fueled by advancements in genomics, biotechnology, and data analytics, which allow for more precise, effective, and personalized treatments. Myelofibrosis serves as a key example in the development of targeted therapies by highlighting critical molecular pathways, such as JAK-STAT signaling. These pathways enable the design of precision treatments such as JAK inhibitors (Ruxolitinib, Fedratinib, and Pacritinib) that help manage symptoms and slow the progression of the disease. For instance, in April 2024, the American Society of Gene & Cell Therapy reported that the number of therapies in clinical development has grown, with Phase I therapies showing the most significant increase, rising by 11%-the highest growth rate since Q4 2022. As a result, the growing demand for targeted therapies is expected to continue driving growth in the myelofibrosis market.

Companies in the myelofibrosis market are focusing on expanding targeted therapies to enhance treatment efficacy, address disease progression, and improve patient outcomes. JAK1/JAK2 inhibitors, for example, target the Janus kinase pathway to reduce inflammation and abnormal blood cell production in myelofibrosis, while ACVR1 inhibitors block activin receptor-like kinase 2 (ALK2) to regulate bone marrow fibrosis and disease progression. A notable example is in September 2023 when GSK plc, a UK-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Ojjaara (momelotinib). This treatment, designed for patients with intermediate- or high-risk myelofibrosis, has a dual mechanism of action that targets both JAK1/JAK2 and ACVR1. It helps regulate inflammatory pathways and improves hemoglobin levels, reducing the need for transfusions. This approval expands treatment options and sets a new standard in the management of MF, particularly for patients struggling with anemia, a significant unmet need in the disease landscape.

In February 2024, Novartis AG, a Swiss pharmaceutical company, acquired MorphoSys AG for EUR 2.7 billion ($2.91 billion). The acquisition enables Novartis to gain full ownership of pelabresib (CPI-0610), a promising treatment for myelofibrosis when combined with ruxolitinib, and tulmimetostat (CPI-0209), an investigational dual EZH1/EZH2 inhibitor being evaluated for solid tumors and lymphomas. This acquisition strengthens Novartis' oncology pipeline by adding innovative therapies aimed at addressing critical unmet medical needs in the field of oncology and myelofibrosis.

Major players in the myelofibrosis (MF) market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., A. Menarini Industrie Farmaceutiche Riunite S.r.l., Incyte Corporation, Sobi Inc., MorphoSys AG, CTI BioPharma Corp., Suzhou Zelgen Biopharmaceutical Co. Ltd., NS Pharma Inc., Impact Biomedicines Inc., Kartos Therapeutics Inc., Geron Corporation.

North America was the largest region in the myelofibrosis (MF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in myelofibrosis (MF) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the myelofibrosis (MF) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myelofibrosis (MF) market consists of revenues earned by entities by providing services such as diagnostic services, patient support programs, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The myelofibrosis (MF) market also includes sales of hematological diagnostic tools, novel fibrosis-targeting drugs, and evolving regenerative therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myelofibrosis (MF) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myelofibrosis (mf) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myelofibrosis (mf) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The myelofibrosis (mf) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Jak Inhibitor; Immunomodulators; Hydroxyurea; Other Drug Types
• 2) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Jak Inhibitor: Ruxolitinib; Fedratinib; Momelotinib; Itacitinib
• 2) By Immunomodulators: Thalidomide; Lenalidomide; Pomalidomide
• 3) By Hydroxyurea: Oral Hydroxyurea; Injectable Hydroxyurea
• 4) By Other Drug Types: Erythropoiesis-Stimulating Agents (ESAs); Danazol; Monoclonal Antibodies; Chemotherapy Agents
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; Novartis AG; GlaxoSmithKline plc; Eli Lilly and Company; Gilead Sciences Inc.; A. Menarini Industrie Farmaceutiche Riunite S.r.l.; Incyte Corporation; Sobi Inc.; MorphoSys AG; CTI BioPharma Corp.; Suzhou Zelgen Biopharmaceutical Co. Ltd.; NS Pharma Inc.; Impact Biomedicines Inc.; Kartos Therapeutics Inc.; Geron Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Myelofibrosis (MF) Market Characteristics

3. Myelofibrosis (MF) Market Trends And Strategies

4. Myelofibrosis (MF) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Myelofibrosis (MF) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Myelofibrosis (MF) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Myelofibrosis (MF) Market Growth Rate Analysis
• 5.4. Global Myelofibrosis (MF) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Myelofibrosis (MF) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Myelofibrosis (MF) Total Addressable Market (TAM)

6. Myelofibrosis (MF) Market Segmentation

• 6.1. Global Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Jak Inhibitor
• Immunomodulators
• Hydroxyurea
• Other Drug Types
• 6.2. Global Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Other Treatment Types
• 6.3. Global Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Myelofibrosis (MF) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Myelofibrosis (MF) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Myelofibrosis (MF) Market, Sub-Segmentation Of Jak Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ruxolitinib
• Fedratinib
• Momelotinib
• Itacitinib
• 6.7. Global Myelofibrosis (MF) Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thalidomide
• Lenalidomide
• Pomalidomide
• 6.8. Global Myelofibrosis (MF) Market, Sub-Segmentation Of Hydroxyurea, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Hydroxyurea
• Injectable Hydroxyurea
• 6.9. Global Myelofibrosis (MF) Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erythropoiesis-Stimulating Agents (ESAs)
• Danazol
• Monoclonal Antibodies
• Chemotherapy Agents

7. Myelofibrosis (MF) Market Regional And Country Analysis

• 7.1. Global Myelofibrosis (MF) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Myelofibrosis (MF) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myelofibrosis (MF) Market

• 8.1. Asia-Pacific Myelofibrosis (MF) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myelofibrosis (MF) Market

• 9.1. China Myelofibrosis (MF) Market Overview
• 9.2. China Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myelofibrosis (MF) Market

• 10.1. India Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myelofibrosis (MF) Market

• 11.1. Japan Myelofibrosis (MF) Market Overview
• 11.2. Japan Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myelofibrosis (MF) Market

• 12.1. Australia Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myelofibrosis (MF) Market

• 13.1. Indonesia Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myelofibrosis (MF) Market

• 14.1. South Korea Myelofibrosis (MF) Market Overview
• 14.2. South Korea Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myelofibrosis (MF) Market

• 15.1. Western Europe Myelofibrosis (MF) Market Overview
• 15.2. Western Europe Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myelofibrosis (MF) Market

• 16.1. UK Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myelofibrosis (MF) Market

• 17.1. Germany Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myelofibrosis (MF) Market

• 18.1. France Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myelofibrosis (MF) Market

• 19.1. Italy Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myelofibrosis (MF) Market

• 20.1. Spain Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myelofibrosis (MF) Market

• 21.1. Eastern Europe Myelofibrosis (MF) Market Overview
• 21.2. Eastern Europe Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myelofibrosis (MF) Market

• 22.1. Russia Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myelofibrosis (MF) Market

• 23.1. North America Myelofibrosis (MF) Market Overview
• 23.2. North America Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myelofibrosis (MF) Market

• 24.1. USA Myelofibrosis (MF) Market Overview
• 24.2. USA Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myelofibrosis (MF) Market

• 25.1. Canada Myelofibrosis (MF) Market Overview
• 25.2. Canada Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myelofibrosis (MF) Market

• 26.1. South America Myelofibrosis (MF) Market Overview
• 26.2. South America Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myelofibrosis (MF) Market

• 27.1. Brazil Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myelofibrosis (MF) Market

• 28.1. Middle East Myelofibrosis (MF) Market Overview
• 28.2. Middle East Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myelofibrosis (MF) Market

• 29.1. Africa Myelofibrosis (MF) Market Overview
• 29.2. Africa Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myelofibrosis (MF) Market Competitive Landscape And Company Profiles

• 30.1. Myelofibrosis (MF) Market Competitive Landscape
• 30.2. Myelofibrosis (MF) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Myelofibrosis (MF) Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Gilead Sciences Inc.
• 31.6. A. Menarini Industrie Farmaceutiche Riunite S.r.l.
• 31.7. Incyte Corporation
• 31.8. Sobi Inc.
• 31.9. MorphoSys AG
• 31.10. CTI BioPharma Corp.
• 31.11. Suzhou Zelgen Biopharmaceutical Co. Ltd.
• 31.12. NS Pharma Inc.
• 31.13. Impact Biomedicines Inc.
• 31.14. Kartos Therapeutics Inc.
• 31.15. Geron Corporation

32. Global Myelofibrosis (MF) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myelofibrosis (MF) Market

34. Recent Developments In The Myelofibrosis (MF) Market

35. Myelofibrosis (MF) Market High Potential Countries, Segments and Strategies

• 35.1 Myelofibrosis (MF) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Myelofibrosis (MF) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Myelofibrosis (MF) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer